Welcome to our dedicated page for Abvc Biopharma SEC filings (Ticker: ABVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ABVC BioPharma, Inc. filings document the regulatory record of a Nevada clinical-stage biopharmaceutical company focused on ophthalmology, CNS, and oncology/hematology programs. The company’s disclosures include Form 8-K reports for financial results and material events, proxy materials for annual shareholder meetings, board elections, and shareholder voting results.
ABVC’s SEC filings also cover governance and capital-structure matters, including unregistered common stock sales under Regulation S, voting-rights proxy arrangements connected to those sales, director and officer compensation arrangements, changes in the company’s independent registered public accounting firm, and formal reporting around shareholder approvals and corporate controls.
ABVC BioPharma reports continued development-stage operations with multiple clinical programs and material losses. The company recorded net losses attributable to ABVC and subsidiaries of $2,257,022 and $942,336 in presented periods, and basic and diluted net loss per share figures shown of $(0.13), $(0.08), $(0.19), and $(0.36) for the periods reported. Current liabilities were stated at $6,532,514 and $6,557,461, and working capital deficits of $(3,762,113) and $(4,377,616) were disclosed. Cash flow provided by financing activities increased to $2,536,083 from $1,726,303, while cash flow used in investing activities was $(665,779).
The filing highlights active R&D: completed Phase II for ABV-1504 (MDD), Phase II Part 1 for ABV-1505 (ADHD) with Part 2 ongoing, planned Phase I for ABV-1601, and ongoing device study ABV-1701 (Vitargus®) in Phase II. Contractual milestone structure for licensing includes aggregate milestone payments of $10 million staged across IND, Phase II, Phase III and NDA events.
ABVC BioPharma, Inc. filed a current report to let investors know it has released its financial results for the second quarter ended June 30, 2025. The company states that these results are presented in a press release dated August 14, 2025, which is included as Exhibit 99.1. This information is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. The report also clarifies that neither the document nor its exhibits constitute an offer to sell or a solicitation to buy any of ABVC’s securities.
ABVC BioPharma received an amended Schedule 13G filed by Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton reporting beneficial ownership of 557,143 shares, equal to 3.2% of the outstanding common stock. The position is composed of 0 currently held common shares, 500,000 B Warrants and 57,143 shares issuable under convertible securities. Lind Global Partners II LLC and Mr. Easton report sole voting and dispositive power over the position.
The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
ABVC BioPharma has filed a Form S-8 registration statement to register an additional 2,515,989 shares of common stock under its Second Amended and Restated 2016 Equity Incentive Plan. The company's authorized capital consists of 100 million shares of common stock and 20 million shares of preferred stock, both with $0.001 par value.
Key details:
- Currently has 16,773,261 shares of common stock outstanding
- No preferred stock currently outstanding
- Classified as a non-accelerated filer and smaller reporting company
- Led by CEO Dr. Uttam Patil, who also serves as Interim CFO
The filing includes comprehensive indemnification provisions for directors and officers under Nevada law (NRS 78.138), protecting them against liability except in cases of intentional misconduct, fraud, or knowing violations of law. The registration statement incorporates by reference various SEC filings from 2025, including annual, quarterly, and current reports.